Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-022520
Filing Date
2025-02-18
Accepted
2025-02-18 17:43:48
Documents
1
Period of Report
2025-02-13

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 5200
  Complete submission text file 0000950170-25-022520.txt   6692
Mailing Address YALELAAN 62 3584 CM UTRECHT P7 3584 CM
Business Address YALELAAN 62 3584 CM UTRECHT P7 3584 CM 31 030 253 8800
Merus N.V. (Issuer) CIK: 0001651311 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O CRISPR THERAPEUTICS AG 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address
Lundberg Sven Ante (Reporting) CIK: 0001682126 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37773 | Film No.: 25636374